Cost-effecttiveness of bemiparin in the prevention and treatment of venous thromboembolism

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 6, Issue 3, 2006, Pages 249-259

  Gómez Outes, Antonio ^a   Berto, Patrizia ^b   Prandoni, Paolo ^c  

^a AUTONOMOUS UNIVERSITY OF MADRID   (Spain)

^b UNIVERSITY OF PADOVA   (Italy)

^c UNIVERSITY OF PADUA MEDICAL SCHOOL   (Italy)

Author keywords

Bemiparin; Cost effectiveness; Heparin; Prophylaxis; Treatment; Venous thromboembolism

Indexed keywords

ACENOCOUMAROL; ALANINE AMINOTRANSFERASE; ANTICOAGULANT AGENT; ANTIVITAMIN K; BADYKET; BEMIPARIN; BLOOD CLOTTING FACTOR 10A INHIBITOR; BMS 56247; DABIGATRAN; DALTEPARIN; DU 176B; ENOXAPARIN; FONDAPARINUX; HEPARIN; IDRAPARINUX; IVOR; LOW MOLECULAR WEIGHT HEPARIN; LY 517717M; NADROPARIN; RIVAROXABAN; RO 11; THROMBIN INHIBITOR; TINZAPARIN; UNCLASSIFIED DRUG; WARFARIN; XIMELAGATRAN; ZIBOR;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTICOAGULATION; BLEEDING; CLINICAL TRIAL; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST MINIMIZATION ANALYSIS; DEEP VEIN THROMBOSIS; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG CHOICE; DRUG COST; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; EPIDURAL HEMATOMA; HEPARIN INDUCED THROMBOCYTOPENIA; HOSPITAL ADMISSION; HOSPITAL CARE; HOSPITAL COST; HUMAN; HYPERBILIRUBINEMIA; HYPERKALEMIA; INJECTION SITE BLEEDING; INJECTION SITE CONTUSION; INJECTION SITE DERMATITIS; LENGTH OF STAY; LIVER DYSFUNCTION; LIVER FAILURE; LONG TERM CARE; LUNG EMBOLISM; META ANALYSIS; NONHUMAN; OSTEOPOROSIS; OUTPATIENT CARE; PHARMACODYNAMICS; POSTOPERATIVE PERIOD; PRIMARY PREVENTION; QUALITY ADJUSTED LIFE YEAR; REVIEW; SPINAL HEMATOMA; STOMACH HEMORRHAGE; SYSTEMATIC REVIEW; TOTAL HIP PROSTHESIS; TOTAL KNEE REPLACEMENT; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

EID: 33745608703     PISSN: 14737167     EISSN: 17448379     Source Type: Journal    
DOI: 10.1586/14737167.6.3.249     Document Type: Review

References (73)

1. Geerts WH, Pineo, GF, Heit JA et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on antithrombotic and thrombolytic therapy. Chest 126(3 Suppi.), 338S-400S (2004).
2. Buller HR, Agnelli G, Hull RD et al. Antithrombotic therapy for venous Thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic therapy. Chest 126(3 Suppl.), 401S-428S(2004).
3. Hirsh J, Raschke R. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126(3 Suppl.), 188S-203S (2004).
4. Matsagas MI. Outpatient treatment of venous thromboembolism using low molecular weight heparins. An overview. Int. Angiol. 23(4), 305-316 (2004).
5. Planès A. Review on bemiparin sodium - a new second-generation low-molecular-weight heparin - and its applications in venous thromboembolism. Expert Opin. Pharmacother. 4(9), 1551-1561 (2003).
6. Ascari E, Siragusa S, Piovella F. The epidemiology of deep vein thrombosis and pulmonary embolism. Haematologica 80(2 Suppl.), 36-41 (1995).
7. Heit JA, Silverstein MD, Mohr DN et al. The epidemiology of venous thromboembolism in the community. Thromb. Haemost. 86(l), 452-463 (2001).
8. Heit JA, Melton LJ III, Lohse CM et al. Incidence of venous thromboembolism in hospitalized patients vs community residents. Mayo Clin. Proc. 76(11), 1102-1110 (2001).
9. Anderson FA Jr, Wheeler HB, Goldberg RJ et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. Arch. Intern. Med. 151(5), 933-938 (1991).
10. Prandoni P, Lensing AW, Cogo A et al. The long-term clinical course of acute deep venous thrombosis. Ann. Intern. Med. 125, 1-7 (1996).
11. Pengo V, Lensing AW, Prins MH et al, Thromboembolic Pulmonary Hypertension Study Group. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N. Engl. J. Med. 350(22), 2257-2264 (2004).
12. Ribeiro A, Lindmarker P, Johnsson H, Juhlin-Dannfelt A, Jorfeldt L. Pulmonary embolism: one-year follow-up with echocardiography doppler and five-year survival analysis. Circulation 99, 1325-1330 (1999).
13. Schafer AI. Venous thrombosis as a chronic disease. N. Engl. J. Med. 340(12), 955-956 (1999).
14. Falkon L, Sáenz-Campos D, Antonijoan R, Martin S, Barbanoj M, Fontcuberta J. Bioavailability and pharmacokinetics of a new low molecular weight heparin (RO- 11). A three way cross-over study in healthy volunteers. Thromb. Res. 78(l), 77-86 (1995).
15. Falkon L, Bayés M, Frontera G, Garí M, Barbanoj M, Fontcuberta J. Pharmacokinetics and tolerability of a new low molecular mass heparin (RO-11) in healthy volunteers - a dose-finding study within the therapeutical range. Thromb. Haemost. 77(l), 133-136 (1997).
16. Racine E. Differentiation of the low-molecular-weight heparins. Pharmacotherapy 21 (Suppl. 2), 62S-70S (2001).
17. Fraxiparine® package insert. Sanofi-Synthélabo Canada Inc., Markham, Ontario (2001).
18. Lovenox® package insert. Aventis Pharmaceuticals Products Inc., NJ, USA (2001).
19. Fragmin® package insert. Pharmacia & Upjohn Company, MI, USA (2001).
20. Innohep® package insert. DuPont Pharma, DE, USA (2001).
21. Borrell M, Antonijoan RM, Ortín R et al. Pharmacokinetic profiles of two LMWH: bemiparin 3,500 IU and enoxaparin 4,000 IU after subcutaneous administration in healthy volunteers. Thromb. Haemost. 86 (Suppl.), CD3578 (2001) (Abstract).
22. Depasse F, González de Suso MJ, Lagoutte I, Fontcuberta J, Borrell M, Samama MM. Comparative study of the pharmacokinetic profiles of two LMWHs - bemiparin (3,500 IU anti-Xa) and tinzaparin (4,500 IU anti-Xa) - administered subcutaneously to healthy male volunteers. Thromb. Res. 109(2-3), 109-117 (2003).
23. Gebska MA, Titley I, Paterson HF et al. High-affinity binding sites for heparin generated on leukocytes during apoptosis arise from nuclear structures segregated during cell death. Blood 99(6), 2221-2227 (2002).
24. Morita S, Gebska MA, Kakkar AK, Scully ME High affinity binding of heparin by necrotic tumour cells neutralises anticoagulant activity - implications for cancer related thromboembolism and heparin therapy. Thromb. Haemost. 86(2), 616-622 (2001).
25. Falkon L, Gari M, Barbanoj M, Amiral J, Fontcuberta J. Tissue factor pathway inhibitor and anti-FXa kinetic profiles of a new low-molecular-mass heparin, bemiparin, at therapeutic subcutaneous doses. Blood Coagul. Fibrinolysis 9(2), 137-141 (1998).
26. Valentin S, Ostergaard P, Kristensen H, Norfang O. Synergism between full length TFPI and heparin. Blood Coagul. Fibrinolysis 3(2), 221-222 (1992).
27. Perez-Ruiz A, Montes R, Carrasco P, Rocha E. Effects of a low molecular weight heparin, bemiparin, and unfractionated heparin on hemostatic properties of endothelium. Clin. Appl. Thromb. Hemost. 8(1), 65-71 (2002).
28. Fareed J, Jeske W, Hoppensteadt D, Clarizio R, Walenga JM. Low-molecular-weight heparins: pharmacologic profile and product differentiation. Am. J. Cardiol. 82(5B), 3L-10L (1998).
29. Cánovas M, De Luna M, Basi N, López-Belmonte L. RO- 11, a new low molecular weight heparin. Proceedings of Advances in Anticoagulant, Antithrombotic and Thrombolytic Drugs. MA, USA (1992).
30. Kakkar VV, Howes J, Sharma V, Kadziola Z. A comparative, double-blind, randomized trial of a new second generation LMWH (bemiparin) and UFH in the prevention of post-operative venous thromboembolism. The Bemiparin Assessment Group. Thromb. Haemost. 83(4), 523-529 (2000).
31. Planès A, Vochelle N, González de Suso MJ, Claracq JP. Prophylactic antithrombotic therapy after orthopaedic surgery using bemiparin, a second-generation low molecular weight heparin. Rev. Anestesiol. Reanim. 48(6), 258-263 (2001). [Article in Spanish].
32. Navarro-Quilis A, Castellet E, Rocha E, Paz-Jiménez J, Planès A. Efficacy and safety of bermiparin compared with enoxaparin in the prevention of venous thromboembolism after total knee arthroplasty. A randomized double-blind clinical trial. J. Thromb. Haemost. 1(3). 425-432 (2003).
33. Abad JI, Gómez-Outes A, Martínez-González J, Maeso R, Rocha E. Observational study of bemiparin, first dose administered 6 hours after surgery, in hip or knee replacement surgery. Pathophysiol. Haemost. Thromb. 33(Suppl. 2), 73 (2003) (Abstract).
34. Fenollosa J, Seminario P. Efficacy and safety of bemiparin in the prophylaxis of venous thromboembolism in orthopedic surgery. Rev. Ortop. Traumatol. 6, 460-465 (2001) [Article in Spanish].
35. Otero-Fernández R, Gómez-Outes A, Martínez-González J, Maeso R, Fontcuberta J. Evaluation of the effectiveness and safety of bemiparin, a second-generation low-molecular-weight heparin, in several orthopaedic settings. Pathophysiol. Haemost. Thromb. 33(Suppl. 2), 61 (2003) (Abstract).
36. Bonal J, Gisbert R. Pharmacoeconomic analysis of the prophylaxis of venous thromboembolic disease in patients undergoing hip arthroplasty. Rev. Esp. Farmacoeconomía 6(1), 17-26 (2000) [Article in Spanish].
37. Moreno González E, Fontcuberta J, de la Llama F, EMRO (Grupo Estudio Mutticéntrico RO-11). Prophylaxis of thromboembolic disease with RO-11 (ROVI), during abdominal surgery. Hepatogastroenterology 43(9), 744-747 (1996).
38. Hidalgo M, Figueroa JM. Prophylaxis of venous thromboembolism in abdominal wall surgery. Hernia 4. 242-247 (2000).
39. Gómez-Outes A, Martínez-González J, del Campo J, Rocha E. Optimal dosing of bemiparin for the prevention of venous thromboembolism in surgery for cancer. Pathophysiol. Haemost. Thromb. 33(Suppl. 2), 78 (2003) (Abstract).
40. Miras-Parra F, Navascués-Martínez E, Gómez-Outes A, Martínez-González J, Rocha E. Utilisation and safety of bemiparin, a low-molecular-weight heparin, in medical patients. A prospective, uncontrolled cohort study. Clin. Drug Invest. 25(7), 463-472 (2005).
41. Kakkar VV, Gebska M, Kadziola Z, Saba N, Carrasco P. Low-molecular-weight heparin in the acute and long-term treatment of deep-vein-thrombosis. Thromb. Haemost. 89(4), 674-680 (2003).
42. Santamaría A, Juárez S, Reche A, Gómez-Outes A, Martínez-González J, Fontcuberta J. Low-molecular-weight heparin, bemiparin, in the outpatient treatment and secondary prophylaxis of venous thromboembolism in standard clinical practice: the ESFERA study. Int. J. Clin. Pract. 60(5), 518-525 (2006).
43. Rocha Hernando E, Soler Marín G, Rosario Díaz E, Pacho Rodríguez J, Monteagudo Ruíz, Martínez-González. Efectividad y seguridad de bemiparina en la. prevención secundaria de la tromboembolia venosa: Un estudio, prospectivo observacional. Haematologica (ed. Esp) 90(Suppl. 2), 135 (2005) (Abstract).
44. Christidou FN, Frangia TK, Bamichas GI et al. Comparison of two low-molecular weight heparins (LMWHs), tinzaparin and bemiparin, during hemodialysis. Int. J. Clin. Pharmacol. Ther 43(7), 335-338 (2005).
45. Horlocker TT, Wedel DJ, Benzon H et al. Regional anesthesia in the anticoagulated patient: defining the risks (the second ASRA Consensus Conference on Neuraxial Anesthesia and Anticoagulation). Reg. Anesth. Pain Med. 28(3), 172-197 (2003).
46. Gómez-Outes A, Maeso R, Moreno A, Martinez-González J. Safety and effectiveness of bemiparin during postmarketing surveillance studies for prevention of venous thromboembolism. Meth. Find. Exp. Clin. Pharmacol. 26(Suppl. A), 155 (2004) (Abstract).
47. Carlson MK, Gleason PP, Sen S. Elevation of hepatic transaminases after enoxaparin use: case report and review of unfractionated and low-molecular-weight heparin-induced hepatotoxicity. Pharmacotherapy 21(1), 108-113 (2001).
48. Al-Mekhaizeem, KA, Sherker AH. Heparininduced hepatotoxicity. Can. J. Gastroenterol. 15(8), 527-530 (2001).
49. Monreal M, Lafoz E, Olive A, del Rio L, Vedia C. Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contraindications to coumarin. Thromb. Haemost. 71(l), 7-11 (1994).
50. Gheno G, Cinetto L, Savarino C et al. Variations of serum potassium level and risk of hyperkalemia in inpatients receiving low-molecular-weight heparin. Eur. J. Clin. Pharmacol. 59(5-6), 373-377 (2003).
51. Rocha E, Gomez-Outes A, Martinez Gonzalez J, Kakkar VV. Effect of unfractionated heparin and long-term treatment with low-molecular-weight heparin, bemiparin, on potassium levels. Thromb. Haemost. 94 (5), 1109-1110 (2005).
52. Honorato J, Gómez-Outes A, Navarro-Quilis A, Martínez-González J, Rocha E, Planès A. Pharmacoeconomic analysis of bemiparin and enoxaparin as prophylaxis for venous thromboembolism in total knee replacement surgery. Pharmacoeconomics 22(13), 885-894 (2004).
53. Gómez-Outes A, Rocha E, Martínez-González J, Kakkar VV. Cost-effectiveness of bemiparin sodium versus unfractionated heparin and oral anticoagulants in the acute and long-term treatment of deep vein thrombosis. Pharmacoeconomics 24(1), 81-92 (2006).
54. Chapman TM, Goa KL. Bemiparin: a review of its use in the prevention of venous thromboembolism and treatment of deep vein thrombosis. Drugs 63(21), 2357-2377(2003).
55. Haentjens P, De Groote K, Annemans L. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. A cost-utility analysis. Arch. Orthop. Trauma Surg. 124(8). 507-517 (2004).
56. Dahl OE, Pleil AM. Investment in prolonged thromboprophylaxis with dalteparin improves clinical outcomes after hip replacement. J. Thromb. Haemost. 1(5), 896-906(2003).
57. Gould MK, Dembitzer AD, Sanders GD, Garber AM. Low molecular weight heparins compared to unfractionated heparin for treatment of acute deep vein thrombosis. A cost-effectiveness analysis. Ann Intern. Med. 130(10), 789-799 (1999).
58. Marchetti M, Pistorio A, Barone M, Serafini S, Barosi G. Low-molecular-weight heparin versus warfarin for secondary prophylaxis of venous thromboembolism: a cost-effectiveness analysis. Am. J. Med. 111(2), 130-139 (2001).
59. Aujesky D, Smith KJ, Cornuz J. Roberts MS. Cost-effectiveness of lowmolecular-weight heparin for secondary prophylaxis of cancer-related venous thromboembolism. Thromb. Haemost. 93(3), 592-599 (2005).
60. van der Heijden JF, Hutten BA, Buller HR et al. Vitamin K antagonists or lowmolecular-weight heparin for the long term treatment of symptomatic venous thromboembolism. Cochrane Database Syst. Rev. 1, CD002001 (2002).
61. Maddineni J, Walenga J, Jeske W, Hoppensteadt D, Fareed J, Messmore H. Therapeutic implications of product individuality in commercially available low molecular weight heparins and their generic versions. Pathophysiol. Haemost. Thromb. 33(Suppl. 2), 61 (2003) (Abstract).
62. Fareed J, Leong WL, Hoppensteadt DA et al. Generic low-molecular-weight heparins: some practical considerations. Semin. Thromb. Hemost. 30(6), 703-713 (2004).
63. Prandoni P. Emerging strategies for treatment of venous thromboembolism. Expert Opin. Emerg. Drugs 10(l), 87-94 (2005).
64. Turpie AG, Bauer KA, Eriksson BI, Lassen MR. Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. Arch. Intern. Med. 162(16), 1833-1840 (2002).
65. Weitz JI, Bates SM. New anticoagulants. J. Thromb. Haemost. 3(8), 1843-1853 (2005).
66. Kubitza D, Becka M, Voith B, Zuehlsdorf M, Wensing G. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor. Clin. Pharmacol. Ther. 78(4), 412-421 (2005).
67. Turpie AG, Fisher WD, Bauer KA et al. BAY 59-7939: an oral, direct Factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase 11 dose-ranging study. J. Thromb. Haemost. 3(11), 2479-2486 (2005).
68. Eriksson BI, Borris L, Dahl OE et al.; ODIXa-HIP Study Investigators. Oral, direct factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement. J. Thromb. Haemost. 4(1), 121-128 (2006).
69. Gulseth MP. Ximelagatran: an orally active direct thrombin inhibitor. Am. J. Health Syst. Pharm. 62(14), 1451-1467 (2005).
70. Kam PC, Kaur N, Thong CL. Direct thrombin inhibitors: pharmacology and clinical relevance. Anaesthesia 60(6), 565-574 (2005).
71. Eriksson BI, Dahl OE, Buller HR et al.; BISTRO II Study Group. A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial. J. Thromb. Haemost. 3(1), 103-111 (2005).
72. Eriksson BI, Dahl OE, Ahnfelt L et al. Dose escalating safety study of a new oral direct thrombin inhibitor, dabigatran etexilate, in patients undergoing total hip replacement: BISTRO I. J. Thromb. Haemost. 2(9), 1573-1580 (2004).
73. Weitz JI. New anticoagulants for treatment of venous thromboembolism. Circulation 110(Suppl. 1), I19-I26 (2004).